Persistent antidepressant effect of low-dose ketamine and activation in the supplementary motor area and anterior cingulate cortex in treatment-resistant depression: A randomized control study

被引:41
|
作者
Chen, Mu-Hong [1 ,2 ]
Li, Cheng-Ta [1 ,2 ,4 ]
Lin, Wei-Chen [2 ,4 ]
Hong, Chen-Jee [1 ,2 ,4 ]
Tu, Pei-Chi [1 ,2 ,3 ]
Bai, Ya-Mei [1 ,2 ]
Cheng, Chih-Ming [2 ]
Su, Tung-Ping [1 ,2 ,3 ,4 ,5 ]
机构
[1] Natl Yang Ming Univ, Fac Med, Div Psychiat, Taipei, Taiwan
[2] Taipei Vet Gen Hosp, Dept Psychiat, 201,Sec 2,Shih-Pai Rd, Taipei 112, Taiwan
[3] Taipei Vet Gen Hosp, Dept Med Res, Taipei, Taiwan
[4] Natl Yang Ming Univ, Inst Brain Sci, Taipei, Taiwan
[5] Gen Cheng Hsin Hosp, Dept Psychiat, Taipei, Taiwan
关键词
Ketamine; Treatment-resistant depression; PET; Supplementary motor area; Dorsal anterior cingulate cortex; UNIPOLAR DEPRESSION; RESIDUAL SYMPTOMS; PREFRONTAL CORTEX; PET SCANS; DISORDER; REMISSION; BRAIN; ADOLESCENTS; OUTCOMES; CARE;
D O I
10.1016/j.jad.2017.09.008
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: A single low-dose ketamine infusion exhibited a rapid antidepressant effect within 1 h. Despite its short biological half-life (approximately 3 h), the antidepressant effect of ketamine has been demonstrated to persist for several days. However, changes in brain function responsible for the persistent antidepressant effect of a single low-dose ketamine infusion remain unclear Methods: Twenty-four patients with treatment-resistant depression (TRD) were randomized into three groups according to the treatment received: 0.5 mg/kg ketamine, 0.2 mg/kg ketamine, and normal saline infusion. Standardized uptake values (SUVs) of glucose metabolism measured through F-18-FDG positron-emission-tomography before infusion and 1 day after a 40-min ketamine or normal saline infusion were used for subsequent whole-brain voxel-wise analysis and were correlated with depressive symptoms, as defined using the Hamilton Depression Rating Scale-17 (HDRS-17) score Results: The voxel-wise analysis revealed that patients with TRD receiving the 0.5 mg/kg ketamine infusion had significantly higher SUVs (corrected for family-wise errors, P = 0.014) in the supplementary motor area (SMA) and dorsal anterior cingulate cortex (dACC) than did those receiving the 0.2 mg/kg ketamine infusion. The increase in the SUV in the dACC was negatively correlated with depressive symptoms at 1 day after ketamine infusion Discussion: The persistent antidepressant effect of a 0.5 mg/kg ketamine infusion may be mediated by increased activation in the SMA and dACC. The higher increase in dACC activation was related to the reduction in depressive symptoms after ketamine infusion. A 0.5 mg/kg ketamine infusion facilitated the glutamatergic neurotransmission in the SMA and dACC, which may be responsible for the persistent antidepressant effect of ketamine much beyond its half-life.
引用
收藏
页码:709 / 714
页数:6
相关论文
共 50 条
  • [21] Treatment response to low-dose ketamine infusion for treatment-resistant depression: A gene-based genome-wide association study
    Chen, Mu -Hong
    Kao, Chung-Feng
    Tsai, Shih-Jen
    Li, Cheng -Ta
    Lin, Wei-Chen
    Hong, Chen-Jee
    Bai, Ya-Mei
    Tu, Pei -Chi
    Su, Tung-Ping
    GENOMICS, 2021, 113 (02) : 507 - 514
  • [22] Low-dose ketamine improved brain network integrity among patients with treatment-resistant depression and suicidal ideation
    Su, Tung-Ping
    Cheng, Li-Kai
    Tu, Pei-Chi
    Chen, Li-Fen
    Lin, Wei-Chen
    Li, Cheng-Ta
    Bai, Ya-Mei
    Tsai, Shih-Jen
    Chen, Mu-Hong
    PSYCHIATRY RESEARCH, 2025, 345
  • [23] Repeated, low-dose oral esketamine in patients with treatment-resistant depression: pilot study
    Smith-Apeldoorn, Sanne Y.
    Veraart, Jolien K. E.
    Ruhe, Henricus G.
    Rot, Marije Ann Het
    Kamphuis, Jeanine
    de Boer, Marrit K.
    Schoevers, Robert A.
    BJPSYCH OPEN, 2021, 8 (01):
  • [24] A Randomized, Double-Blind, Midazolam-Controlled Trial of Low-Dose Ketamine Infusion in Patients With Treatment-Resistant Depression and Prominent Suicidal Ideation
    Su, Tung-Ping
    Li, Cheng-Ta
    Lin, Wei-Chen
    Wu, Hui-Ju
    Tsai, Shih-Jen
    Bai, Ya-Mei
    Mao, Wei-Chung
    Tu, Pei-Chi
    Chen, Li-Fen
    Li, Wei-Chi
    Chen, Mu-Hong
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2023, 26 (05): : 331 - 339
  • [25] Safety, Tolerability, and Clinical Effect of Low-Dose Buprenorphine for Treatment-Resistant Depression in Midlife and Older Adults
    Karp, Jordan F.
    Butters, Meryl A.
    Begley, Amy E.
    Miller, Mark D.
    Lenze, Eric J.
    Blumberger, Daniel M.
    Mulsant, Benoit H.
    Reynolds, Charles F., III
    JOURNAL OF CLINICAL PSYCHIATRY, 2014, 75 (08) : E785 - E793
  • [26] ADJUNCT LOW-DOSE LITHIUM-CARBONATE IN TREATMENT-RESISTANT DEPRESSION - A PLACEBO-CONTROLLED STUDY
    ZUSKY, PM
    BIEDERMAN, J
    ROSENBAUM, JF
    MANSCHRECK, TC
    GROSS, CC
    WEILBERG, JB
    GASTFRIEND, DR
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1988, 8 (02) : 120 - 124
  • [27] Antisuicidal effect, BDNF Val66Met polymorphism, and low-dose ketamine infusion: Reanalysis of adjunctive ketamine study of Taiwanese patients with treatment-resistant depression (AKSTP-TRD)
    Chen, Mu-Hong
    Lin, Wei-Chen
    Wu, Hui-Ju
    Cheng, Chih-Ming
    Li, Cheng-Ta
    Hong, Chen-Jee
    Tu, Pei-Chi
    Bai, Ya-Mei
    Tsai, Shih-Jen
    Su, Tung-Ping
    JOURNAL OF AFFECTIVE DISORDERS, 2019, 251 : 162 - 169
  • [28] Monoamine neurotransmitter-related gene-based genome-wide association study of low-dose ketamine in patients with treatment-resistant depression
    Kao, Chung-Feng
    Tsai, Shih-Jen
    Su, Tung-Ping
    Li, Cheng-Ta
    Lin, Wei-Chen
    Hong, Chen-Jee
    Bai, Ya-Mei
    Tu, Pei-Chi
    Chen, Mu-Hong
    JOURNAL OF PSYCHOPHARMACOLOGY, 2025,
  • [29] Low-Dose Augmentation With Buprenorphine for Treatment-Resistant Depression: A Multisite Randomized Controlled Trial With Multimodal Assessment of Target Engagement
    Lee, Hyewon H.
    Blumberger, Daniel M.
    Lenze, Eric J.
    Anderson, Stewart J.
    Barch, Deanna M.
    Black, Kevin J.
    Cristancho, Pilar
    Daskalakis, Zafiris J.
    Eisenstein, Sarah A.
    Huang, Yiyun
    Li, Songye
    Lissemore, Jennifer
    McConathy, Jonathan
    Mulsant, Benoit H.
    Rajji, Tarek K.
    Reynolds III, Charles F.
    Su, Yi
    Tu, Zhude
    Voineskos, Daphne
    Karp, Jordan F.
    BIOLOGICAL PSYCHIATRY: GLOBAL OPEN SCIENCE, 2022, 2 (02): : 127 - 135
  • [30] Current Suicide Risk, but Not Lifetime History of Attempted Suicide, Predicts Treatment Response to Low-Dose Ketamine Infusion: Post Hoc Analysis of Adjunctive Ketamine Study of Taiwanese Patients With Treatment-Resistant Depression
    Lin, Wei-Chen
    Su, Tung-Ping
    Li, Cheng-Ta
    Tsai, Shih-Jen
    Tu, Pei-Chi
    Bai, Ya-Mei
    Chen, Mu-Hong
    EXPERIMENTAL AND CLINICAL PSYCHOPHARMACOLOGY, 2024, 32 (01) : 84 - 89